PCRX-201 knee injection for painful knee osteoarthritis, tested for safety
Tests the safety of PCRX-201 injected into the knee in people with osteoarthritis.
Key facts
- Who runs it
- Pacira Pharmaceuticals, Inc
- Where
- Altoona, Atlanta, Baltimore, Beverly Hills, Birmingham, Brooklyn, Charleston, Chicago, Chula Vista, Collierville, Columbia, Covina, Dallas, Dayton, Daytona Beach, Duncansville, Houston, Huntington Beach, La Mesa, Lake Charles, Las Vegas, Lewisville, Lincoln, Morehead City, New Orleans, New York, Oldsmar, Phoenix, Plantation, Rochester Hills, Santa Monica, Sarasota, West Hills, West Palm Beach, Whittier, Wilmington, and Winter Park, United StatesSee the 40 sites
- Trial code
- Registry title
- A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 135 people, planned
- Started
- 26 Feb 2025
- Expected to end
- Jul 2032
- Type of study
- Interventional, 6 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Enekinragene Inzadenovec (PCRX-201)
- Placebo
- Record updated
- 25 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 45 to 80 with painful knee osteoarthritis and active joint lining inflammation (synovitis) in the knee. It tests one knee injection of PCRX-201 against placebo.
- Age
- 45 to 80 years
- Sex
- All sexes
- Disease stage
- Knee osteoarthritis symptoms for ≥12 months. Knee pain on >15 days in the last month. Average daily knee pain score between ≥5.0 and ≤9.0. K-L Grade 2, 3 or 4 on X-ray (Part A) or K-L Grade 2 or 3 (Part B). BMI ≤40 kg/m2.
- Earlier treatment
- At least 2 past treatments for the knee must have failed in the past 12 months: structured land-based exercise (may include physical therapy) and another conservative therapy, such as nonselective NSAIDs or COX-2 inhibitors. No knee joint injections of drugs or biologics within 6 months, no knee steroid injections within 3 months, and no gene therapy in the past 3 years.
- Biomarker or test result
- Active synovitis in the knee on ultrasound Doppler (Part A) or contrast-enhanced MRI (Part B). Moderate or severe synovitis on MRI (Part A), or synovitis score ≥5 on the Guermazi scale (Part B).
Main reasons for not taking part
- Autoimmune connective tissue disease, gout or pseudogout, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis or other inflammatory arthritis
- Any active infection, including in the knee
- Unable to have an MRI with contrast
- Unstable knee joint, such as a torn anterior cruciate ligament, within 12 months
- For Part B: any past surgery on the knee being studied
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Subjects must be willing and able to comply with the study procedures and visit schedule and able to follow verbal and written instructions
- Subjects must be male or female and 45 to 80 years old, inclusive, at Screening
- Subjects must exhibit symptoms associated with osteoarthritis of the index knee for ≥12 months before Screening (subject self-reporting is acceptable)
- Subjects must have index knee pain for >15 days over the last month before Screening (subject self-reporting is acceptable)
- Subjects must have received 2 or more failed 2 or more therapies: Restricted physical activity as per Osteoarthritis Research Society International (OARSI) core level recommendation, ie, "structured land-based exercise" (this may include physical therapy), and failure of an additional type of conservative therapy for OA of the index knee, eg, nonselective NSAIDs or COX-2 inhibitors, in the past 12 months
- Subjects must have a body mass index (BMI) ≤40 kg/m2 at Screening
- Subjects must have an index knee examination indicating the index knee and the intended injection site area are free of any signs of local or joint infection at Baseline
- Subjects must have an index knee Average Daily Knee Pain (NRS) between ≥5.0 and ≤9.0 at Screening and Baseline
- Sexually active subjects of child-bearing potential (SOCBP) and their partners must agree to use effective birth control while in the study
- Subjects must have active synovitis in the index knee as determined by ultrasound Doppler (Part A only) For Part B, participants must have active synovitis in the index knee as determined by contrast-enhanced MRI
- Subjects must exhibit American College of Rheumatology Criteria (clinical and radiological) for osteoarthritis as follows:; Knee pain; At least 1 of the following:; Age >50 years ii. Morning stiffness <30 minutes iii. Crepitus on knee motion c. Osteophytes
- Subjects must have K-L Grade 2, 3, or 4 (Part A) or K-L Grade 2 or 3 (Part B) in the index knee based on X-rays performed during Screening and confirmed by trained radiographers at a central facility before enrollment
- Subjects need to show the presence of moderate or severe synovitis based on 11-point synovitis score using contrast-enhanced MRI (Part A). For Part B, participants need to show the presence of synovitis ≥5 on the Guermazi synovitis scoring scale using contrast-enhanced MRI to be enrolled
Who cannot take part
- Subjects have any current or prior diagnosis of autoimmune connective tissue disorders, secondary OA conditions, benign synovial tumors, gout/pseudogout, reactive arthritis, RA, psoriatic arthritis, ankylosing spondylitis, or arthritis associated with inflammatory bowel disease
- Subjects are receiving or have received any gene therapy treatment (eg, IL-1Ra) in the past 3 years
- Subjects have used IA steroids ≤3 months before screening
- For Part B, subjects with any surgery related tot he index knee; Other protocol-defined criteria apply
- Subjects have any active systemic or local infection, including infection of the index knee
- Subjects have used any approved or investigational IA drug/biologic in index knee within 6 months of Screening (eg, hyaluronic acid, platelet rich plasma, stem cells, prolotherapy, and amniotic fluid injection)
- Subjects are unable to undergo MRI with contrast MRI
- Subjects with X-ray or MRI exclusionary events
- Subjects have an unstable index knee joint (eg, torn anterior cruciate ligament) within 12 months of Screening
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 45 and 80 years old?
Where in United States
- University Orthopedics CenterAltoona, United StatesContact: Jill FrembergNot yet recruiting
- Pinnacle Trials, IncAtlanta, United StatesContact: Robert RobbinsNot yet recruiting
- Lifebridge HealthBaltimore, United StatesContact: Taj Jamal AndrewsNot yet recruiting
- Osteoporosis Medical CenterBeverly Hills, United StatesContact: Lisa Ramsay, MANo longer taking part
- Flourish Research - BirminghamBirmingham, United StatesContact: Melissa MartinNot yet recruiting
- Alabama Clinical Therapeutics, LLCBirmingham, United StatesContact: Lisa Ramsay, MANo longer taking part
- NY ScientificBrooklyn, United StatesContact: Mohammed HossainNot yet recruiting
- Clinical Trials of South Carolina - CharlestonCharleston, United StatesContact: Lisa Ramsay, MANo longer taking part
- Rush Medical College - Division of RheumatologyChicago, United StatesContact: Joshlean FairNot yet recruiting
- Advanced Clinical Research Center, LLC dba TriWest Research Associates, LLCChula Vista, United StatesContact: Daniela CardenasNot yet recruiting
- Campbell ClinicCollierville, United StatesContact: Margaret KnackNot yet recruiting
- Clinical Trials of South Carolina - ColumbiaColumbia, United StatesContact: Lisa Ramsay, MANo longer taking part
- Medvin Clinical Research - CovinaCovina, United StatesContact: Rosalia ThanoryNot yet recruiting
- Helios CR, Inc.Dallas, United StatesContact: Sammi SwaimNot yet recruiting
- Zenos Clinical ResearchDallas, United StatesContact: Lisa Ramsay, MANo longer taking part
- META Medical Research InstituteDayton, United StatesContact: Benu KulkarniNot yet recruiting
- Arrow Clinical TrialsDaytona Beach, United StatesContact: Vinoothna MoluguriTaking people
- Altoona Center For Clinical ResearchDuncansville, United StatesContact: Lisa Ramsay, MANo longer taking part
- Accurate Clinical Research, Inc - HoustonHouston, United StatesContact: Philip Waller (principal investigator)Not yet recruiting
- Beach Physicians Medical Group Inc.Huntington Beach, United StatesContact: Kim ZepedaTaking people
- Horizon Clinical ResearchLa Mesa, United StatesContact: Lisa Ramsay, MANo longer taking part
- Accurate Clinical Research Inc. - Lake CharlesLake Charles, United StatesContact: Enrique Mendez (principal investigator)Not yet recruiting
- Excel Clinical ResearchLas Vegas, United StatesContact: Lisa Ramsay, MANo longer taking part
- Epic Clinical ResearchLewisville, United StatesContact: Lisa Ramsay, MANo longer taking part
- Physicians Research CollaborationLincoln, United StatesContact: Brittany PresnellTaking people
- West Clinical ResearchMorehead City, United StatesContact: Millicent ClarkNot yet recruiting
- Best Clinical Trials, LLCNew Orleans, United StatesContact: Mary Lalla LaneNot yet recruiting
- New York University (NYU) Center for Musculoskeletal CareNew York, United StatesContact: Nathan HanNot yet recruiting
- Journey Research Inc.Oldsmar, United StatesContact: Lisa Ramsay, MANo longer taking part
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - PhoenixPhoenix, United StatesContact: Nathaly NavarroNot yet recruiting
- OrthoArizonaPhoenix, United StatesContact: Robert WallaceNot yet recruiting
- Discovery Health Research Center - Plantation, FLPlantation, United StatesContact: Joel HernandezNot yet recruiting
- Michigan Orthopaedic and Spine SurgeonsRochester Hills, United StatesContact: Cecile PestanoNot yet recruiting
- Source HealthcareSanta Monica, United StatesContact: Gabriel WirnowskiNot yet recruiting
- Gulfcoast Research InstituteSarasota, United StatesContact: Jesse D'AlessioNot yet recruiting
- Alliance Clinical West Hills (Focus Clinical Research)West Hills, United StatesContact: Lisa Ramsay, MANo longer taking part
- Palm Beach Research CenterWest Palm Beach, United StatesContact: Lisa Ramsay, MANo longer taking part
- Medvin Clinical Research - WhittierWhittier, United StatesContact: Tien-I Karleen Su (principal investigator)Not yet recruiting
- M3 Wake Research - Wilmington, NCWilmington, United StatesContact: Jeremy Hoff (principal investigator)Not yet recruiting
- Conquest ResearchWinter Park, United StatesContact: Lisa Ramsay, MANo longer taking part
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn if a single knee injection of different doses (Dose A and Dose B) of an investigation product PCRX-201, following steroid pretreatment, is safe and tolerable in male of female patients 45 to 80 years old with osteoarthritis of the knee. It will also learn how the body reacts to the PCRX-201 injection and how effective the treatment is.
Read full original descriptionShow less
Researchers will compare Dose A and Dose B of PCRX-201 versus placebo from Week 1 through Week 52 to assess adverse events. Researchers will also explore how PCRX-201 may impact knee pain and joint function over time.
Participants will be asked to
* Visit the clinic for pretreatment and drug administration * Visit the clinic for checkups and tests:
1. Screening through Week 52: intially weekly, bi-weekly, later monthly 2. Week 53 through Week 260 (Year 5): 8 visits throughout the period
The 6 groups in the trial
- Part A Dose ATreatment being tested
Single Intra-Articular injection
Treatment: Enekinragene Inzadenovec (PCRX-201)
- Part A, PlaceboPlacebo, for comparison
Single Intra-Articular injection
Treatment: Placebo
- Part B Dose ATreatment being tested
Single Intra-Articular injection
Treatment: Enekinragene Inzadenovec (PCRX-201)
- Part B Dose BTreatment being tested
Single Intra-Articular injection
Treatment: Enekinragene Inzadenovec (PCRX-201)
- Part B PlaceboPlacebo, for comparison
Treatment: Placebo
- Part A, Dose BTreatment being tested
Single Intra-Articular injection
Treatment: Enekinragene Inzadenovec (PCRX-201)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase 2, Two-Part, Randomized, Double-Blind, Active-Controlled Study to Assess the Safety and Tolerability of Enekinragene Inzadenovec (PCRX-201) in Subjects With Painful Osteoarthritis of the Knee
- Plain-language title
- PCRX-201 knee injection for painful knee osteoarthritis, tested for safetyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT06884865, who can take part
- Record updated
- 25 August 2026